Matches in SemOpenAlex for { <https://semopenalex.org/work/W2396153577> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2396153577 endingPage "7" @default.
- W2396153577 startingPage "514" @default.
- W2396153577 abstract "To investigate the clinic predictors of efficacy and adverse events of sorafenib in treating with advanced hepatocellular carcinoma (HCC) patients.From December 2008 to October 2011, 54 patients received sorafenib for unresectable or metastatic HCC. There were 46 male and 8 female patients. The mean age was 48.7 years (ranging from 21 to 77 years). Patients received sorafenib orally 400 mg twice daily on a continuous dosing schedule with 6 weeks counting as a single cycle. Tumor response was assessed according to the Response Evaluation Criteria in Solid Tumor and toxicity grading was performed using the National Cancer Institute Common Toxicity Criteria version 3.0. The relationship between different clinic variable factors and curative effects of sorafenib was analyzed by using Cox proportion hazard regression analysis.HCC was etiological related to HBV in 52 patients (96.3%). Following sorafenib therapy, 2 patients (3.7%) achieved a partial response and 24 patients (44.4%) achieved stable disease, with a disease control rate of 48.1%. The median time to progression (TTP) was 3.8 months. Multivariate analysis showed that greater Child and Eastern Cooperative Oncology Group (ECOG) grade were independent predictors of shorter TTP (HR = 1.361, 95%CI: 1.081 - 12.665, P = 0.041; HR = 1.449, 95%CI: 1.151 - 12.305, P = 0.032). The common adverse events were hand-foot syndrome (64.8%), alopecia (46.3%), and diarrhea (44.4%).Single-agent sorafenib demonstrates good efficacy and acceptable tolerability in treating advanced HCC. The presents of Child class A and ECOG performance grade 0 predict better response to sorafenib in advanced HCC patients." @default.
- W2396153577 created "2016-06-24" @default.
- W2396153577 creator A5003554962 @default.
- W2396153577 creator A5016536540 @default.
- W2396153577 creator A5017541508 @default.
- W2396153577 creator A5024656427 @default.
- W2396153577 creator A5058548650 @default.
- W2396153577 creator A5086345836 @default.
- W2396153577 date "2012-06-01" @default.
- W2396153577 modified "2023-10-12" @default.
- W2396153577 title "[Clinic predictors of efficacy and adverse events of sorafenib therapy for advanced hepatocellular carcinoma patients]." @default.
- W2396153577 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22943944" @default.
- W2396153577 hasPublicationYear "2012" @default.
- W2396153577 type Work @default.
- W2396153577 sameAs 2396153577 @default.
- W2396153577 citedByCount "0" @default.
- W2396153577 crossrefType "journal-article" @default.
- W2396153577 hasAuthorship W2396153577A5003554962 @default.
- W2396153577 hasAuthorship W2396153577A5016536540 @default.
- W2396153577 hasAuthorship W2396153577A5017541508 @default.
- W2396153577 hasAuthorship W2396153577A5024656427 @default.
- W2396153577 hasAuthorship W2396153577A5058548650 @default.
- W2396153577 hasAuthorship W2396153577A5086345836 @default.
- W2396153577 hasConcept C126322002 @default.
- W2396153577 hasConcept C141071460 @default.
- W2396153577 hasConcept C143998085 @default.
- W2396153577 hasConcept C197934379 @default.
- W2396153577 hasConcept C207103383 @default.
- W2396153577 hasConcept C2776694085 @default.
- W2396153577 hasConcept C2777288759 @default.
- W2396153577 hasConcept C2777793932 @default.
- W2396153577 hasConcept C2778019345 @default.
- W2396153577 hasConcept C2778375690 @default.
- W2396153577 hasConcept C2778695046 @default.
- W2396153577 hasConcept C2778822529 @default.
- W2396153577 hasConcept C2779984678 @default.
- W2396153577 hasConcept C44249647 @default.
- W2396153577 hasConcept C50382708 @default.
- W2396153577 hasConcept C71924100 @default.
- W2396153577 hasConcept C90924648 @default.
- W2396153577 hasConceptScore W2396153577C126322002 @default.
- W2396153577 hasConceptScore W2396153577C141071460 @default.
- W2396153577 hasConceptScore W2396153577C143998085 @default.
- W2396153577 hasConceptScore W2396153577C197934379 @default.
- W2396153577 hasConceptScore W2396153577C207103383 @default.
- W2396153577 hasConceptScore W2396153577C2776694085 @default.
- W2396153577 hasConceptScore W2396153577C2777288759 @default.
- W2396153577 hasConceptScore W2396153577C2777793932 @default.
- W2396153577 hasConceptScore W2396153577C2778019345 @default.
- W2396153577 hasConceptScore W2396153577C2778375690 @default.
- W2396153577 hasConceptScore W2396153577C2778695046 @default.
- W2396153577 hasConceptScore W2396153577C2778822529 @default.
- W2396153577 hasConceptScore W2396153577C2779984678 @default.
- W2396153577 hasConceptScore W2396153577C44249647 @default.
- W2396153577 hasConceptScore W2396153577C50382708 @default.
- W2396153577 hasConceptScore W2396153577C71924100 @default.
- W2396153577 hasConceptScore W2396153577C90924648 @default.
- W2396153577 hasIssue "6" @default.
- W2396153577 hasLocation W23961535771 @default.
- W2396153577 hasOpenAccess W2396153577 @default.
- W2396153577 hasPrimaryLocation W23961535771 @default.
- W2396153577 hasRelatedWork W1584669207 @default.
- W2396153577 hasRelatedWork W1892405924 @default.
- W2396153577 hasRelatedWork W2000774941 @default.
- W2396153577 hasRelatedWork W2150962876 @default.
- W2396153577 hasRelatedWork W2264866072 @default.
- W2396153577 hasRelatedWork W2370121646 @default.
- W2396153577 hasRelatedWork W2396153577 @default.
- W2396153577 hasRelatedWork W2410776349 @default.
- W2396153577 hasRelatedWork W3032619395 @default.
- W2396153577 hasRelatedWork W4211239810 @default.
- W2396153577 hasVolume "50" @default.
- W2396153577 isParatext "false" @default.
- W2396153577 isRetracted "false" @default.
- W2396153577 magId "2396153577" @default.
- W2396153577 workType "article" @default.